Abstract
Abstract Lymphoma is a heterogeneous group of malignancies derived from the lymphoid system that accounts for roughly 4 % of cancers worldwide. A significant improvement during the last decade was made possible with the introduction of an anti-CD20 monoclonal antibody, rituximab, which has been utilized widely in the treatment of B cell lymphomas leading to significantly better outcomes, which in part have contributed to the reduced mortality rates. Various factors like lifestyle, genetics, environment, age, ethnicity and gender are risk factors of lymphoma. Other factors include Socioeconomics, marital status, educational background, history of drinking or smoking and obesity. Globally, lymphoma is the sixth most common malignancy. HL is second most common lymphoma in developed countries whereas third most common malignancy in developing countries. NHL is eleventh most occurring cancer in males and eighth most common in female. Lymphoma is more common in men. In Pakistan HL accounts for 4.9% and NHL is approximately 4.7%. Prevalence of lymphoma cancer in Balochistan is about 9.6%. Keywords: Angiogenic; Biological markers; Epidemiology; Hodgkin lymphoma; Lymphoma; Non-Hodgkin lymphoma http://dx.doi.org/10.19045/bspab.2019.80039
Highlights
Lymphoma is a heterogeneous group of malignancies derived from the lymphoid system that accounts for roughly 4 % of cancers worldwide
Lymph angiogenesis is a process through which lymphatic system grows parallel with blood vascular system
During normal physiology network of vessels through lymphatic system plays vital role e.g. tissue fluid homeostasis maintained by lymphatic capillaries which absorb extravagated fluid and transfer that again to venous circulation through superior lymphatic vessels
Summary
IFRT (Involve-Field Radio Therapy) is an active and less toxic in HL early stages together with unfavorable and favorable conditions. Monoclonal antibody like Rituximab is a unique antibody used for NHL treatment This antibody has high binding affinity to those cells that contains CD20 antigen on the surface of benign and cancerous B-cells. By adding rituximab in CHOP and applying eight cycles with freshly diagnosed DLBCL old patients show complete response and this treatment low the treatment failure rates and increases overall survival by comparing CHOP alone [110]. Rituximab with CVP (cyclophosphamide, vincristine, and prednisone) is standard treatment for follicular lymphoma, which has 60% to 80% response rates. The current research is meant to enable Government has to establish cancer hospital in Balochistan in order to provide people of Balochistan the facilities to get cancer treatment Better survival of this disease is linked with increasing awareness among the population. Authors’ contributions Conceived and designed the study: S Shabbir, Analyzed the data: S Shabbir, Wrote the paper: S Shabbir
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
